A biweekly DPP ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial

Documents similaires

• Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial
  par: Congqing Pan, et autres
  Publié: (2025)
• Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial
  par: Yingying Xiang, et autres
  Publié: (2024)
• Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
  par: Leili Gao, et autres
  Publié: (2024)
• A phase 2, randomized, multicenter, double‐blind, placebo‐controlled trial of S‐adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer's disease
  par: Sarah Holper, et autres
  Publié: (2026)
• Influence of impaired glucose tolerance alone and combined with metabolic syndrome on long‐term risk of cardiovascular events and mortality
  par: Fei Chen, et autres
  Publié: (2024)